Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01542879 · ClinicalTrials.gov registry record · Phase 1

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

A Phase 1 study of Cancer, sponsored by Heike E Daldrup-Link.

Recruiting
Registry status
Phase 1
Development phase
75
Enrollment target
1
Study location

NCT01542879 is a Phase 1 study of Cancer that is actively recruiting participants, run by Heike E Daldrup-Link. The registered enrollment target is 75 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01542879, a Phase 1 study of Cancer, is actively recruiting participants, sponsored by Heike E Daldrup-Link.

RECRUITING
Registry status
Phase 1
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

A research study on the diagnosis of spread of disease for children who have been diagnosed with solid tumors using a new whole body imaging technique and a new MR contrast agent (ferumoxytol). Standard tests that are used to determine the extent and possible spread of a child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG) scanning. The purpose of this study is to determine if newer imaging tests referred to as whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The advantage of the new imaging test is that it is associated with no or significantly reduced radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole body MR and PET/MR will be compared with that of the conventional, standard imaging studies for tumor detecting.

Conditions Studied

Cancer

Interventions

  • DRUG Ferumoxytol
  • PROCEDURE WB-DW-MR scan
  • PROCEDURE 18-F-FDG PET scan
  • PROCEDURE 18-F-FDG PET/MR scan

Study Locations (1)

California

  • Stanford University Cancer Institute - Stanford

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2012-02
Est. Completion 2026-12
Phase Phase 1

Sponsor

Heike E Daldrup-Link

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01542879

The ClinicalTrials.gov registry entry for NCT01542879 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Heike E Daldrup-Link, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which Ferumoxytol is the first listed.

NCT01542879 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01542879 about?

NCT01542879 is a clinical study titled "Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer". A research study on the diagnosis of spread of disease for children who have been diagnosed with solid tumors using a new whole body imaging technique and a new MR contrast agent (ferumoxytol). Standard tests that are used to determine the extent and possible spread of a child's disease include magn...

What is the current status of trial NCT01542879?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2012-02. Estimated completion is 2026-12.

What conditions does trial NCT01542879 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT01542879?

The interventions under investigation include: Ferumoxytol (DRUG), WB-DW-MR scan (PROCEDURE), 18-F-FDG PET scan (PROCEDURE), 18-F-FDG PET/MR scan (PROCEDURE).

Who is sponsoring clinical trial NCT01542879?

This trial is sponsored by Heike E Daldrup-Link, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01542879 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.